Share Price | PharmaCyte Biotech, Inc. Stock Analysis & Recommendation

Q: How big is PharmaCyte Biotech, Inc.?

Market Cap: As of Jun 18, PharmaCyte Biotech, Inc. has a market capitalization of 7.28 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, PharmaCyte Biotech, Inc. reported net sales of 0.00 million and a net profit of 20.25 million.Balance Sheet Snapshot: As of Apr 24, the company reported shareholder's funds of 39.51 million and total assets of 59.90 million.

Q: What does PharmaCyte Biotech, Inc. do?

Overview: PharmaCyte Biotech, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.Financial Snapshot: Net Profit: -3 Million (Quarterly Results - Jan 2025) Market Cap: USD 7.28 Million (Micro Cap)Key Metrics: P/E: 0.00 Debt Equity: -0.42 Return on Equity: 43.35% Price to Book: 0.18 Contact Details: Registrar Address: Not available.

Q: Is PharmaCyte Biotech, Inc. overvalued or undervalued?

As of 3 October 2023, PharmaCyte Biotech, Inc. has moved from fair to overvalued. The company currently exhibits a price-to-earnings ratio of 45.2, a price-to-book ratio of 5.6, and a debt-to-equity ratio of 0.1, which indicates a relatively high valuation compared to its earnings and assets. When compared to peers such as Amgen Inc. with a P/E ratio of 22.5 and Gilead Sciences, Inc. at 11.8, PharmaCyte's valuation appears excessive.Overall, the analysis suggests that PharmaCyte Biotech is overvalued given its high ratios in relation to industry standards. This valuation is further supported by the company's recent stock performance, which has lagged behind the Sensex, reinforcing the notion that the current market price may not accurately reflect its underlying value.

Q: Is PharmaCyte Biotech, Inc. technically bullish or bearish?

As of 11 September 2025, the technical trend for PharmaCyte Biotech, Inc. has changed from mildly bearish to sideways. The current technical stance is neutral, with a mix of indicators showing both bullish and bearish signals. The MACD is mildly bullish on both the weekly and monthly time frames, while the KST is mildly bullish weekly but bearish monthly. The moving averages indicate a mildly bearish stance on the daily chart, and Bollinger Bands are bearish on the weekly and mildly bearish on the monthly. Despite the mildly bullish indicators, the stock has underperformed significantly compared to the S&P 500 across multiple periods, with a year-to-date return of -38.17% versus the S&P 500's 12.22%, and a one-year return of -49.70% compared to the S&P 500's 17.14%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

118.39 k

Shareholding (Oct 2025)

FII

3.21%

Held by 6 FIIs

DII

92.13%

Held by 5 DIIs

Promoter

0.00%

How big is PharmaCyte Biotech, Inc.?

22-Jun-2025

As of Jun 18, PharmaCyte Biotech, Inc. has a market capitalization of 7.28 million, with net sales of 0.00 million and a net profit of 20.25 million over the latest four quarters. The company reported shareholder's funds of 39.51 million and total assets of 59.90 million as of Apr 24.

View full answer

What does PharmaCyte Biotech, Inc. do?

22-Jun-2025

PharmaCyte Biotech, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit of -$3 million and a market cap of $7.28 million. Key metrics include a P/E ratio of 0.00 and a return on equity of 43.35%.

View full answer

Is PharmaCyte Biotech, Inc. overvalued or undervalued?

25-Jun-2025

As of October 3, 2023, PharmaCyte Biotech, Inc. is considered overvalued due to its high price-to-earnings ratio of 45.2 and price-to-book ratio of 5.6, especially when compared to peers like Amgen and Gilead, alongside its recent underperformance against the Sensex.

View full answer

Is PharmaCyte Biotech, Inc. technically bullish or bearish?

20-Sep-2025

As of September 11, 2025, PharmaCyte Biotech, Inc. shows a neutral technical trend with mixed indicators, including mildly bullish MACD signals, but has significantly underperformed the S&P 500 with year-to-date and one-year returns of -38.17% and -49.70%, respectively.

View full answer

Compare PharmaCyte Biotech, Inc. with Similar Stocks

Paranovus Entertainment Technology Ltd.Neptune Wellness Solutions, Inc.Upexi, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 9 Million ()

P/E

0.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.43

Return on Equity

-7.41%

Price to Book

0.25

Revenue and Profits:

Net Sales:

(Quarterly Results - Apr 2025)

Net Profit:

12 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-21.35%

6 Months

-29.96%

1 Year

-54.55%

2 Years

-68.61%

3 Years

-76.43%

4 Years

-66.67%

5 Years

3788.89%

PharmaCyte Biotech, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-3.05%

EBIT to Interest (avg)

-6.76

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.42

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

12.74%

ROCE (avg)

ROE (avg)

9.07%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

0.17

EV to EBIT

2.17

EV to EBITDA

2.17

EV to Capital Employed

-0.42

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

43.35%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Oct 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 4 Schemes (4.66%)

Foreign Institutions

Held by 6 Foreign Institutions (3.21%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Apr'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Apr 2025 is 0.00% vs 0.00% in Apr 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Apr 2025 is 800.00% vs 1,400.00% in Apr 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Apr'25",
        "Apr'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.00",
          "val2": "-1.20",
          "chgp": "16.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "12.60",
          "val2": "3.10",
          "chgp": "306.45%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "11.70",
          "val2": "1.30",
          "chgp": "800.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Apr'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Apr 2025 is 0.00% vs 0.00% in Apr 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Apr 2025 is 10,133.33% vs 106.98% in Apr 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Apr'25",
        "Apr'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.40",
          "val2": "-6.50",
          "chgp": "32.31%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "12.20",
          "val2": "4.80",
          "chgp": "154.17%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "30.70",
          "val2": "0.30",
          "chgp": "10,133.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Apr'25 - YoY

Apr'25

Apr'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-1.00

-1.20

16.67%

Interest

0.00

Exceptional Items

12.60

3.10

306.45%

Consolidate Net Profit

11.70

1.30

800.00%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Apr 2025 is 0.00% vs 0.00% in Apr 2024

Consolidated Net Profit

YoY Growth in quarter ended Apr 2025 is 800.00% vs 1,400.00% in Apr 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Apr'25

Apr'25

Apr'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-4.40

-6.50

32.31%

Interest

0.00

Exceptional Items

12.20

4.80

154.17%

Consolidate Net Profit

30.70

0.30

10,133.33%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Apr 2025 is 0.00% vs 0.00% in Apr 2024

Consolidated Net Profit

YoY Growth in year ended Apr 2025 is 10,133.33% vs 106.98% in Apr 2024

All Annual Results

Company CV

About PharmaCyte Biotech, Inc.

PharmaCyte Biotech, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

PharmaCyte Biotech, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is PharmaCyte Biotech, Inc.?

Watch in Real-Time

What does PharmaCyte Biotech, Inc. do?

Is PharmaCyte Biotech, Inc. overvalued or undervalued?

Is PharmaCyte Biotech, Inc. technically bullish or bearish?

Compare PharmaCyte Biotech, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Oct 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Apr'25 - YoY

Annual Results Snapshot (Consolidated) - Apr'25

About PharmaCyte Biotech, Inc.

Company Coordinates